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Summary The use of older generation antiepileptic drugs (AEDs) during pregnancy
is known to be associated with a two- to threefold increased risk of birth defects in the
offspring and possible also other adverse outcomes in the exposed infant. Much less
has been known about newer generation AEDs in this respect. Recent studies based on
national registries as well as specific epilepsy and pregnancy registries are beginning
to provide information on comparative teratogenic effects of different AEDs. Hence,
the prevalence of birth defects appears to be higher with exposure to valproate
compared with carbamazepine and possibly also in comparison with lamotrigine.
Further studies based on larger cohorts are needed to compare AEDs at different
dosages and to analyse the possible impact of confounding factors. Furthermore, data
is insufficient to assess the human teratogenic potential of other newer generation
AEDs than lamotrigine.
Retrospective and a few small prospective studies suggest that exposure to
valproate also might be associated with a lower verbal IQ at school age, but further
prospective studies are needed to draw firm conclusions.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Numerous studies have attempted to assess the
teratogenic effects of antiepileptic drugs (AEDs)
since the first observations of an association
between use of anticonvulsants and an increased
risk of birth defects were published 40 years ago.1
Despite differences in study design and populations,
most have confirmed an increased risk of adverse
pregnancy outcome with exposure to the older gen-
eration AEDs such as phenobarbital, phenytoin, car-* Corresponding author at: Department of Neurology, Karolinska
Hospital, SE-171 76 Stockholm, Sweden. Tel.: +46 851773705;
fax: +46 851773757.
E-mail address: torbjorn.tomson@karolinska.se (T. Tomson).
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doi:10.1016/j.seizure.2007.11.016bamazepine and valproate. Potential adverse fetal
effects of these drugs include intrauterine growth
retardation, dysmorphisms, major congenital mal-
formations and delay in postnatal cognitive devel-
opment. Although it is evident that the vast
majority of women with epilepsy who are on treat-
ment with these AEDs during pregnancy give birth to
perfectly normal children, these potential terato-
genic effects are amajor concern for all womenwith
epilepsy that are of childbearing potential. Unlike
many other medications, antiepileptic drug treat-
ment generally cannot be withdrawn even when
pregnancy is planned, since uncontrolled seizures
may be harmful to the mother as well as the fetus.
The risks associated with uncontrolled seizures thus
have to be balanced against the teratogenic risks. Published by Elsevier Ltd. All rights reserved.
Teratogenic effects of antiepileptic drugs 167imposed by the AEDs. The challenge is to identify
the most appropriate AED for the individual patient,
with respect to seizure control as well as develop-
mental toxicity, and to use that drug in a way that
controls seizures with minimised risks to the mother
as well as the fetus.
The number of treatment options has increased
substantially with the introduction of several newer
AEDs the last 15 years. Furthermore, recent studies
have provided new information on the teratogenic
potential of the different older and newer genera-
tion AEDs thus facilitating more rational approaches
to the management of women with epilepsy con-
sidering pregnancy. This paper will review suchmore
recent data on teratogenic effects of AEDs with
emphasis on major congenital malformations and
postnatal cognitive development.Methodological aspects
Several different methods have been used to assess
the teratogenic effects of AEDs. For obvious reasons
they all share the limitation of being observational
studies rather than randomised trials. The selection
of a particular AED, or the dosage, depends on
individual factors such as type of epilepsy and sei-
zures, seizure frequency, co-morbidity and socio-
economic circumstances, factors that could be
linked to the risk of malformations. An association
between a specific treatment and outcome can thus
not automatically be interpreted as evidence of a
causal relationship. The potential impact of con-
founding factors needs to be taken into account in
the interpretation of the associations.
Reporting and recall bias are other important
sources for misinterpretations when retrospective
data are used. As an example, the spontaneous
reporting of pregnancy outcome to manufacturers
of AEDs are likely to suffer from selective reporting
of adverse outcomes. Case-control designs may be
useful for uncommon outcomes but is associated
with the risk of recall bias. Existing registries of
e.g., drug prescriptions and cross-linkage with regis-
tries of birth defects has been useful. Some such
registries are nationwide and population-based.
Unfortunately, they generally lack detail and infor-
mation on other factors that could contribute to the
outcome. Cohort studies are another common
approach. Such studies can be retrospective or
prospective. Retrospective identification of the
cohort is associated with the risk of selection bias,
whereas prospective studies ideally identify and
enrol women with epilepsy before any information
on pregnancy outcome is known, thus avoiding the
risk of selection bias. A special type of cohortstudies, antiepileptic drugs and pregnancy regis-
tries, has been established lately. These registries
are prospective observational studies enrolling
women with epilepsy early in pregnancy collecting
information on drug exposure and other potential
risk factors before outcome of the pregnancy is
known. Outcome in terms of occurrence of birth
defects in the offspring is recorded. These registries
can collect high numbers of pregnancies, the type of
drug exposure is ideally recorded in an unbiased way
without prior knowledge of teratogenic outcome,
and detailed data on other relevant patient char-
acteristics could be obtained. The internal validity
of the risk assessments is high but it is essential that
the impact of possible confounders is included in the
analyses. A potential problem with the pregnancy
registries is the generalizability of the observations,
which will depend on how pregnancies were
enrolled.
Cohort studies of long-term postnatal outcome
pose additional methodological challenges. In addi-
tion to the difficulties in keeping drop-out rates low
the impact of environmental confounding factors
will increase with the duration of follow-up.
It is thus important to pay attention to metho-
dological issues such as statistical power, reliability
of collected data, and attempts to control for appro-
priate confounding factors in the analyses, rather
than to just compare rates of adverse pregnancy
outcome in published studies.Major malformations
Most studies report a two- to threefold increase in
risk of major malformations among the offspring of
women that are treated for epilepsy during preg-
nancy.2—5 The pathogenesis is likely to be multi-
factorial, including genetic predisposition, socio-
economic circumstances, seizures and epilepsy,
and it has long been debated whether maternal
epilepsy per se is associated a greater risk of mal-
formations in the offspring. However, a recent
meta-analysis suggested that the malformation rate
among offspring of women with untreated epilepsy
was similar to that among non-epilepsy controls.6
The available data thus strongly suggests that AEDs
are the major cause for the increased risk of these
adverse outcomes.
Polytherapy with AEDs has in general been asso-
ciated with a higher malformation rate than mono-
therapy.3,5,7—11 This has been a consistent finding
throughout most studies. However, different AED
combinations are likely to vary in their teratogenic
potential. Some have been suggested to be asso-
ciated with particularly high malformation rates,
168 T. Tomson, D. Battinoe.g., the combination of carbamazepine, phenobar-
bital and valproate among older generation AEDs.12
More recent studies have also indicated a con-
siderable risk with valproate in combination with
lamotrigine.11,13 The International Lamotrigine
Pregnancy Registry reported major malformations
in 12.5% of children exposed to this specific combi-
nation compared with 2.9% in lamotrigine mono-
therapy.13 Morrow et al. found birth defects among
9.6% of the offspring of mothers treated with valpro-
ate and lamotrigine combined, versus in 3.2% asso-
ciated with lamotrigine monotherapy and 6.2% in
monotherapy with valproate.11 Although interest-
ing, these observations need to be interpreted with
great caution since factors such as differences in
drug dosages and severity of the maternal epilepsy
may contribute.
A dose—effect relationship of valproate terato-
genicity has been reported in several studies.
Dosages above 800—1000 mg/day have been asso-
ciated with significantly higher malformation rates
than lower dosages.3,5,7,10,14 One recent study also
reported a positive dose response for major con-
genital malformations with lamotrigine exposure.
Doses above 200 mg/day were associated with
higher risks.11 This, however, was not confirmed
in the manufacturer’s own lamotrigine pregnancy
registry.15
A major concern for women with epilepsy con-
sidering pregnancy, and for their physicians, is if
AEDs differ with respect to fetal risks. Here data are
less conclusive. However, the pattern of malforma-
tions varies. Heart defects seem to dominate among
children exposed to barbiturates, and to some
extent phenytoin and carbamazepine, whereas
neural tube defects and hypospadia are more com-
mon among offspring of mothers taking valproate
during pregnancy. The risk of neural tube defects in
association with valproate has been estimated to 1—
2% of exposed infants.16 Valproate has also been
associated with skeletal abnormalities.17 An
increased risk of neural tube defects of 0.5—1%,
has also been reported after carbamazepine expo-
sure.18 Recently, lamotrigine has been reported to
be associated with a significant increase in the risk
of non-syndromic oral clefts.19
Although AEDs apparently vary in the spectrum of
malformations that they are associated with, earlier
studies have failed to demonstrate differences in
the overall teratogenic potential between different
AEDs. This may be explained by methodological
shortcomings and in particular lack of statistical
power due to insufficient numbers of pregnancies.
Large studies with thousands of pregnancies are
needed considering the number of treatment
options that are available and the potential con-founding factors that need to be taken into account.
Population-based national registries have been uti-
lized to analyse the risk of birth defects with dif-
ferent AEDs. The Swedish Medical Birth Registry
recently published a report based on 1398 pregnan-
cies with exposure to AEDs.9 The risk for a severe
malformation in the offspring was greater after
exposure to valproate (n = 268) compared with car-
bamazepine monotherapy (n = 703), odds ratio (OR)
2.59 (95% CI: 1.43—4.68).9 The Finnish drug pre-
scription database and the National Medical Birth
Registry were utilized to identify 1411 pregnancies
with AED exposure.10 The risk of malformations
was higher in children exposed to valproate mono-
therapy (malformation rate 10.7%; OR = 4.18; 2.31—
7.57) than of untreated patients. In contrast, the
risk of malformations was not elevated in associa-
tion with exposure to carbamazepine, oxcarbaze-
pine, or phenytoin monotherapy.
However, realising that even larger studies are
needed, epilepsy and pregnancy registries have been
established in different regions of the world. These
are prospective observational studies aiming to enrol
large numbers of AED exposed pregnancies and pro-
viding outcomes assessment in terms of birth defects
in the offspring. Using slightly different methodolo-
gies such registries have been established in North
America, the UK, Australia, and Europe. The Eur-
opean registry (EURAP) has been enlarged to include
also collaborators in Asia, Oceania, South America,
and Australia.20 EURAPhas not yet released outcome
data in relation to individual AEDs,whereas the other
registries have published such information. Table 1
provides a summary ofmalformation rates in associa-
tion with exposure to different AEDs in monotherapy
from the pregnancy registries and other major stu-
dies in recent years. Malformation rates with carba-
mazepine exposure have ranged from 2.2 to 7.9%,
with lamotrigine from 0 to 4.4%, phenobarbital from
2.9 to 10.4%, phenytoin from 0.7 to 9.1%, and with
valproate from 5.7 to 16.8% (Table 1). The wide
ranges in malformation rates reflect differences in
study populations but probably most importantly
differences in methodology. Methods for follow-up
and recording of outcomes vary as well as the criteria
for malformations. Prevalences of malformations
with different AEDs should therefore not be com-
pared across studies. The so far largest cohort with
data on different AEDs is the report from the UK
Register, which demonstrated a greater risk for mal-
formations with valproate compared to carbamaze-
pine.11 However, even within-study comparisons
should be interpreted with caution considering the
possible effects of confounding factors.
The manufacturer GlaxoSmithKline has set up
a separate registry for lamotrigine pregnancies.
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.7 Among 802 prospective monotherapy exposures,
major birth defects occurred in 22 (2.7%; 1.8—
4.2%),15 but the registry lacks an internal compar-
ison. With the exception of lamotrigine, information
on the newer generation AEDs is particularly scarce.
In one case-series, all of 35 pregnancies with oxcar-
bazepinemonotherapy enrolled at any stage prior to
birth had normal outcome, while 1 of 20 pregnancies
with oxcarbazepine as combination therapy
resulted in a cardiac malformation.25 In the drug-
prescription registry-based study from Finland,
Artama et al reported one uro-genital malformation
among 99 pregnancies with oxcarbazepine mono-
therapy.10 Of 16 retrospectively or prospectively
enrolled women taking gabapentin as monotherapy
from onset of pregnancy, one resulted in an infant
born with one kidney.26 The UK Register has pub-
lished separately on outcome in association with
levetiracetam exposure.27 Three of 117 infants of
women treated with levetiracetam during preg-
nancy had major congenital malformations, 2.7%
(95% CI: 0.9—7.7%). None was among the 39 exposed
to levetiracetam in monotherapy. These studies are
clearly too small to allow firm conclusions as to the
teratogenic potential of levetiracetam, oxcarbaze-
pine or gabapentin.Postnatal cognitive development
The possibility that AED exposure during pregnancy
may adversely affect postnatal development of the
offspring has previously been assessed in several
small-scale studies. In a Cochrane review, Adab
concluded that the majority of these studies are
of limited quality and that there is little evidence
about which drugs carry more risks than others to
the development of children exposed.28 Since then,
a few studies have been published indicating that
exposure in utero to valproate might be associated
with specific adverse cognitive effects in the
child.29—31 A retrospective study from the UK found
significantly lower verbal IQ in 41 children exposed
to valproate monotherapy than in un-exposed and in
children exposed to carbamazepine (n = 52) or phe-
nytoin (n = 21).29 Multiple regression analysis iden-
tified exposure to valproate, five or more tonic—
clonic seizures in pregnancy and low maternal IQ to
be associated with lower verbal IQ also after adjust-
ment for confounding factors. Valproate doses
above 800 mg/day were associated with lower ver-
bal IQ than lower doses. These important signals still
have to be interpreted with some caution given the
small numbers, the retrospective nature of the
study and the fact that only 40% of eligible mothers
agreed to participate.
170 T. Tomson, D. BattinoA small prospective population-based study from
Finland found a lower verbal IQ in children exposed
in utero to valproate and to polytherapy in general
compared with non-exposed children or children
exposed to carbamazepine.30 However, this study
could not demonstrate an independent effect of
valproate because of small numbers (13 children
exposed to valproate monotherapy) and since the
results were confounded by low maternal education
and polytherapy. Another small prospective popula-
tion-based Finnish study signals a similar trend for
worse outcome in verbal IQ in children exposed to
valproate.31
Although conclusive evidence is lacking, the sig-
nals concerning potential adverse effects on post-
natal development of particularly valproate need to
be considered seriously and adequately sized pro-
spective studies are urgently needed.Conclusions
Although the majority of women with epilepsy give
birth to healthy children, there is a two- to three-
fold increase in the risk of major congenital mal-
formations in the offspring. This increase is mainly
due to the teratogenic effects of AEDs. Recent
studies suggest that the prevalence of birth defects
might be higher with exposure to valproate com-
pared with carbamazepine and possibly also in
comparison with lamotrigine. Further studies based
on larger cohorts are needed to compare AEDs at
different dosages and to analyse the possible
impact of confounding factors. Data is insufficient
to assess the human teratogenic potential of other
newer generation AEDs.
Important signals indicate that exposure to
valproate in utero may be associated with a lower
verbal IQ at school age, but further prospective
studies are needed.
While the observations of potential differences
between AEDs in teratogenic potential are relevant
for treatment decisions, these must be weighed
against possible differences in effectiveness against
the seizure disorder. The overall aim of the treat-
ment should be to use the AED that can control
tonic—clonic seizures with minimised risks to the
mother as well as the fetus.References
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